TY - JOUR AU - Yao, C. AU - Liu, J. AU - Shao, L. PY - 2011 DA - 2011// TI - Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin JO - Hepatogastroenterology VL - 58 ID - Yao2011 ER - TY - JOUR AU - Li, V. S. AU - Wong, C. W. AU - Chan, T. L. AU - Chan, A. S. AU - Zhao, W. AU - Chu, K. M. PY - 2005 DA - 2005// TI - Mutations of PIK3CA in gastric adenocarcinoma JO - BMC Cancer VL - 5 UR - https://doi.org/10.1186/1471-2407-5-29 DO - 10.1186/1471-2407-5-29 ID - Li2005 ER - TY - JOUR AU - Lim, T. AU - Lee, J. AU - Lee, D. J. AU - Lee, H. Y. AU - Han, B. AU - Baek, K. K. PY - 2011 DA - 2011// TI - Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer JO - Cancer Chemother Pharmacol VL - 68 UR - https://doi.org/10.1007/s00280-011-1653-5 DO - 10.1007/s00280-011-1653-5 ID - Lim2011 ER - TY - JOUR AU - Lee, S. J. AU - Lee, J. AU - Park, S. H. AU - Park, J. O. AU - Park, Y. S. AU - Lim, H. Y. PY - 2013 DA - 2013// TI - Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients JO - Invest New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-013-0022-0 DO - 10.1007/s10637-013-0022-0 ID - Lee2013 ER - TY - JOUR AU - Doi, T. AU - Muro, K. AU - Boku, N. AU - Yamada, Y. AU - Nishina, T. AU - Takiuchi, H. PY - 2010 DA - 2010// TI - Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.2923 DO - 10.1200/JCO.2009.26.2923 ID - Doi2010 ER - TY - JOUR AU - Ji, D. AU - Zhang, Z. AU - Cheng, L. AU - Jinjia, C. AU - Shanshan, W. AU - Biqiang, Z. PY - 2014 DA - 2014// TI - The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0085116 DO - 10.1371/journal.pone.0085116 ID - Ji2014 ER - TY - JOUR AU - Ohtsu, A. AU - Ajani, J. A. AU - Bai, Y. X. AU - Bang, Y. J. AU - Chung, H. C. AU - Pan, H. M. PY - 2013 DA - 2013// TI - Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.3552 DO - 10.1200/JCO.2012.48.3552 ID - Ohtsu2013 ER - TY - JOUR AU - Yoon, D. H. AU - Ryu, M. H. AU - Park, Y. S. AU - Lee, H. J. AU - Lee, C. AU - Ryoo, B. Y. PY - 2012 DA - 2012// TI - Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum JO - Br J Cancer VL - 106 UR - https://doi.org/10.1038/bjc.2012.47 DO - 10.1038/bjc.2012.47 ID - Yoon2012 ER - TY - JOUR AU - Bjornsti, M. A. AU - Houghton, P. J. PY - 2004 DA - 2004// TI - The TOR pathway: a target for cancer therapy JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1362 DO - 10.1038/nrc1362 ID - Bjornsti2004 ER - TY - JOUR AU - O’Reilly, T. AU - McSheehy, P. M. PY - 2010 DA - 2010// TI - Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals JO - Transl Oncol VL - 3 UR - https://doi.org/10.1593/tlo.09277 DO - 10.1593/tlo.09277 ID - O’Reilly2010 ER - TY - JOUR AU - Bu, Z. AU - Ji, J. PY - 2013 DA - 2013// TI - Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer JO - Curr Cancer Drug Targets VL - 13 UR - https://doi.org/10.2174/1568009611313020002 DO - 10.2174/1568009611313020002 ID - Bu2013 ER - TY - JOUR AU - Vazquez-Martin, A. AU - Oliveras-Ferraros, C. AU - Colomer, R. AU - Brunet, J. AU - Menendez, J. A. PY - 2008 DA - 2008// TI - Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdm589 DO - 10.1093/annonc/mdm589 ID - Vazquez-Martin2008 ER - TY - JOUR AU - Meric-Bernstam, F. AU - Akcakanat, A. AU - Chen, H. AU - Do, K. A. AU - Sangai, T. AU - Adkins, F. PY - 2012 DA - 2012// TI - PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2123 DO - 10.1158/1078-0432.CCR-11-2123 ID - Meric-Bernstam2012 ER - TY - JOUR AU - Janku, F. AU - Hong, D. S. AU - Fu, S. AU - Piha-Paul, S. A. AU - Naing, A. AU - Falchook, G. S. PY - 2014 DA - 2014// TI - Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors JO - Cell Rep VL - 6 UR - https://doi.org/10.1016/j.celrep.2013.12.035 DO - 10.1016/j.celrep.2013.12.035 ID - Janku2014 ER - TY - JOUR AU - Byun, D. S. AU - Cho, K. AU - Ryu, B. K. AU - Lee, M. G. AU - Park, J. I. AU - Chae, K. S. PY - 2003 DA - 2003// TI - Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma JO - Int J Cancer VL - 104 UR - https://doi.org/10.1002/ijc.10962 DO - 10.1002/ijc.10962 ID - Byun2003 ER - TY - JOUR AU - Sun, D. AU - Toan, X. AU - Zhang, Y. AU - Chen, Y. AU - Lu, R. AU - Wang, X. PY - 2008 DA - 2008// TI - Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines JO - Sci China C Life Sci VL - 51 UR - https://doi.org/10.1007/s11427-008-0080-2 DO - 10.1007/s11427-008-0080-2 ID - Sun2008 ER - TY - JOUR AU - Han, X. AU - Ji, Y. AU - Zhao, J. AU - Xu, X. AU - Lou, W. PY - 2013 DA - 2013// TI - Expression of PTEN and mTOR in pancreatic neuroendocrine tumors JO - Tumour Biol VL - 34 UR - https://doi.org/10.1007/s13277-013-0849-1 DO - 10.1007/s13277-013-0849-1 ID - Han2013 ER - TY - JOUR AU - Nishi, T. AU - Iwasaki, K. AU - Ohashi, N. AU - Tanaka, C. AU - Kobayashi, D. AU - Nakayama, G. PY - 2013 DA - 2013// TI - Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells JO - Cancer Lett VL - 331 UR - https://doi.org/10.1016/j.canlet.2013.01.004 DO - 10.1016/j.canlet.2013.01.004 ID - Nishi2013 ER - TY - JOUR AU - Maj-Hes, A. AU - Medioni, J. AU - Scotte, F. AU - Schmidinger, M. AU - Kramer, G. AU - Combe, P. PY - 2013 DA - 2013// TI - Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy JO - Oncology VL - 85 UR - https://doi.org/10.1159/000350005 DO - 10.1159/000350005 ID - Maj-Hes2013 ER - TY - JOUR AU - Vazquez-Martin, A. AU - Oliveras-Ferraros, C. AU - Cufi, S. AU - Barco, S. AU - Martin-Castillo, B. AU - Menendez, J. A. PY - 2011 DA - 2011// TI - Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth JO - J Cell Physiol VL - 226 UR - https://doi.org/10.1002/jcp.22333 DO - 10.1002/jcp.22333 ID - Vazquez-Martin2011 ER - TY - JOUR AU - Gajria, D. AU - Chandarlapaty, S. PY - 2011 DA - 2011// TI - HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies JO - Expert Rev Anticancer Ther VL - 11 UR - https://doi.org/10.1586/era.10.226 DO - 10.1586/era.10.226 ID - Gajria2011 ER - TY - JOUR AU - Feng, Y. AU - Ma, P. C. PY - 2011 DA - 2011// TI - Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer JO - Cancer Discov VL - 1 UR - https://doi.org/10.1158/2159-8290.CD-11-0289 DO - 10.1158/2159-8290.CD-11-0289 ID - Feng2011 ER - TY - JOUR AU - Catenacci, D. V. AU - Henderson, L. AU - Xiao, S. Y. AU - Patel, P. AU - Yauch, R. L. AU - Hegde, P. PY - 2011 DA - 2011// TI - Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence JO - Cancer Discov VL - 1 UR - https://doi.org/10.1158/2159-8290.CD-11-0175 DO - 10.1158/2159-8290.CD-11-0175 ID - Catenacci2011 ER - TY - JOUR AU - Santoni, M. AU - Pantano, F. AU - Amantini, C. AU - Nabissi, M. AU - Conti, A. AU - Burattini, L. PY - 1845 DA - 1845// TI - Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma JO - Biochim Biophys Acta VL - 2014 ID - Santoni1845 ER -